ATHA Profile
Athira Pharma, Inc., headquartered in Bothell, Washington, is a late clinical-stage biopharmaceutical company dedicated to developing innovative therapies aimed at restoring neuronal health and mitigating neurodegeneration. Founded in 2011 and formerly known as M3 Biotechnology, Inc. before rebranding in April 2019, Athira Pharma is at the forefront of pioneering small molecule treatments designed to address critical unmet needs in neurodegenerative diseases.
The company’s lead product candidate, ATH-1017, is a small molecule that penetrates the blood-brain barrier and acts as a positive modulator of the HGF/MET pathway. This compound is currently undergoing advanced clinical trials for Alzheimer’s disease, with ongoing Phase 3 trials under the LIFT-AD study and Phase 2 trials under the ACT-AD study. ATH-1017 is also being evaluated in Phase 2 clinical trials for Parkinson’s disease, highlighting Athira Pharma’s commitment to addressing a broad spectrum of neurodegenerative disorders with potential disease-modifying therapies.
In addition to ATH-1017, Athira Pharma is advancing other product candidates that are in the preclinical stage. These include ATH-1019, which is being developed for peripheral nervous system indications, and ATH-1020, which targets neuropsychiatric conditions. These candidates represent the company's strategic focus on expanding its portfolio to encompass a wide range of neurological and psychiatric disorders, with the aim of developing novel treatments that can significantly impact patient outcomes.
Athira Pharma’s innovative approach and robust pipeline reflect its dedication to transforming the treatment landscape for neurodegenerative diseases. By leveraging its expertise in small molecule development and focusing on critical areas of unmet medical need, the company is positioned to make substantial contributions to the field of neurology and psychiatry. Athira Pharma continues to advance its clinical programs and preclinical research, striving to bring forward new therapeutic options that could offer hope to patients suffering from debilitating neurological conditions.
|
